

# Assessment of ventilation inhomogeneity in patients with alpha-1-antitrypsin deficiency- A useful tool for monitoring early lung disease



Susanne I Fuchs<sup>1</sup>, Matthias Griese<sup>2</sup>, Doris Staab<sup>3</sup>, Robert Bals<sup>4</sup>, Monika Gappa<sup>1</sup>

<sup>1</sup>Marien Hospital Wesel, Department of Paediatrics and Research Institute, GERMANY;

<sup>2</sup>Dr. von Haunersches Kinderspital, Medical University Munich, GERMANY; <sup>3</sup>Charité Berlin, GERMANY

<sup>4</sup>University of Saarland, Homburg, GERMANY

## INTRODUCTION

The risk of developing alpha-1-antitrypsin deficiency ( $\alpha$ 1-AT deficiency) related emphysema during adulthood is high in patients with a PiZZ genotype. Currently, the FEV<sub>1</sub> is used for detecting and monitoring  $\alpha$ 1-AT deficiency related lung disease. However it is likely that the early changes occur in peripheral airways that are not accessible by spirometry. Multiple breath washout (MBW) is a sensitive test for detecting ventilation inhomogeneity (VI) within the peripheral airways. VI can be quantified by calculating several indices such as the Lung Clearance Index (LCI).

## AIM

The aim of the present study is to assess the clinical value of measuring the LCI in patients with  $\alpha$ 1-AT deficiency.

## METHOD

Patients were recruited from the German Alpha 1 registry and through patient organisations. For this preliminary analyses, data sets from 3 centers were included.

Children, adolescents and adults with confirmed  $\alpha$ 1-AT deficiency (PiZZ) and healthy controls performed 2-3 single nitrogen washout tests (MBW<sub>N<sub>2</sub></sub>) using the EasyOne Pro LAB™ (ndd Switzerland) with 100% oxygen.




Figure 1: Screenshot of an MBW test in a control subject with real time traces of flow (blue) and molar mass (green) and automated analysis




Figure 2: Screenshot of an MBW test in a patient with real time traces of flow (blue) and molar mass (green) and automated analysis

## RESULTS

46 patients with  $\alpha$ 1-AT deficiency and PiZZ genotype (6.4-73.4 years) and 40 healthy controls (6.9-84.4 years) were included in this preliminary analysis. Mean (SD) LCI was 10.50 (2.91) in patients with  $\alpha$ 1-AT deficiency and 6.5 (0.72) in controls. The mean difference (95% ci, p-value) of the LCI between the groups was -3.980 (-4.872;-3.089, <0.001). Within-test repeatability (CV%) was 7.2% in patients with  $\alpha$ 1-AT deficiency and 5.6% in controls. Correlation between LCI and age was significant in patients (p=<0.001) but not in controls (p= 0.076).




Figure 3: Individual Lung Clearance Index (LCI) versus age in patients (●) and controls (○)

## DISCUSSION

Assessment of LCI derived from MBW<sub>N<sub>2</sub></sub> was feasible, reproducible and well tolerated in both, patients with  $\alpha$ 1-AT deficiency and controls. LCI differed significantly between patients and controls. Individual data demonstrated a marked discrimination between the groups. VI increased with age in patients. We conclude from these preliminary data that the LCI reflects the presence of VI and may be a useful additional lung function parameter in patients with  $\alpha$ 1-AT deficiency. However, further analyses will reveal the relation between LCI and other lung function parameters, particularly in early stages of disease.